Form 4: Intra-Cellular Therapies EVP, Chief Commercial Officer Mark Neumann Sells Shares to Cover Tax Obligations

Mark Neumann, EVP, Chief Commercial Officer of Intra-Cellular Therapies, Inc., sold shares of common stock between March 7 and March 11, 2024, to cover tax liabilities arising from the vesting of restricted stock units, pursuant to a pre-arranged Rule 10b5-1 trading plan.

Summary

• Mark Neumann, the EVP, Chief Commercial Officer of Intra-Cellular Therapies, Inc., filed a Form 4 detailing changes in beneficial ownership.
• The transactions involved the sale of common stock between March 7, 2024, and March 11, 2024.
• These sales were executed under a Rule 10b5-1 trading plan adopted on March 14, 2023.
• A majority of the proceeds from these sales will be used to cover Neumann's tax liability arising from the vesting of restricted stock units.
• On March 7, 2024, Neumann sold 8,636 shares at a weighted average price of $66.37 and 4,496 shares at a weighted average price of $66.95.
• On March 10, 2024, 7,345 restricted stock units converted into common stock.
• On March 11, 2024, Neumann sold 4,303 shares at a weighted average price of $65.11, 1,729 shares at a weighted average price of $65.92, and 1,313 shares at a weighted average price of $66.86.
• Following these transactions, Neumann directly owns 29,700 shares of common stock.

Sentiment

Score: 6

Explanation: The document is neutral. It simply reports transactions related to stock sales for tax purposes under a pre-existing plan. There is no indication of positive or negative sentiment.

Industry Context

Insider sales are a common occurrence, especially when related to covering tax obligations from vesting equity. The use of a pre-arranged 10b5-1 trading plan suggests the sales were planned and not based on any specific non-public information.

Stakeholder Impact

• The stock sales by a company executive could have a minor negative impact on shareholder sentiment, although the pre-planned nature of the sales mitigates this concern.

Key Dates